We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Idera Pharmaceuticals Announces Selection of Toll-like Receptor (TLR) Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck
News

Idera Pharmaceuticals Announces Selection of Toll-like Receptor (TLR) Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck

Idera Pharmaceuticals Announces Selection of Toll-like Receptor (TLR) Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck
News

Idera Pharmaceuticals Announces Selection of Toll-like Receptor (TLR) Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Idera Pharmaceuticals Announces Selection of Toll-like Receptor (TLR) Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

"We are very pleased to have created multiple novel TLR agonists for Merck's exclusive evaluation and use as vaccine adjuvants," commented Sudhir Agrawal, D Phil, Chairman and Chief Executive Officer of Idera. "Our chemistry-based approach for creating TLR-targeted compounds has allowed us to achieve the objective of generating a broad range of TLR-targeted agonists, each with a unique immune response profile. We look forward to Merck's continued development of these compounds."

"We continue to make progress in our license and research agreement with Idera," said John Shiver, vice president of vaccines discovery at Merck. "Collaborations such as this are essential as we seek to evaluate new innovative approaches to vaccine discovery and development."

Advertisement